Subscribe to our Newsletters !!
Climate change is very disruptive to the Amazon ra
By 2024, there are certain things you need to do i
Insects that are given more attention and reverenc
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
New Delhi, Dec 3 (PTI) Drug firm Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator for Metolazone tablets, indicated for the treatment of salt and water retention caused by heart failure or kidney disease. The approved product is therapeutically equivalent to the reference listed drug product Zaroxolyn Tablets 2.5 mg, 5 mg and 10 mg of Lannett Company, Inc..
In a regulatory filing, Alembic Pharmaceuticals stated”it has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Metolazone tablets USP 2.5 mg, 5 mg, and 10 mg”.
Metolazone tablets are indicated for the treatment of salt and water retention such as edema accompanying congestive heart failure, edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function.
Metolazone tablets are also indicated for the treatment of hypertension, either alone or in combination with other antihypertensive drugs of another class.
Quoting IQVIA data, Alembic Pharma stated Metolazone tablets USP 2.5 mg, 5 mg, and 10 mg have an estimated market size of USD 33 million to 12 months ending September 2020.
PTI SVK ANS ANS
